Drug Trial Radar · NCT05814926
GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Apr 26, 2023
Primary completion
Aug 3, 2023
Study completion Oct 20, 2023
Sponsor
- Lead sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 68 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to test whether mild (Child-Pugh A, score 5-6) and moderate (Child-Pugh B, score 7-9) hepatic impairment affects pharmacokinetics, safety and tolerability of GP681, compared with a control group with normal hepatic function following oral administration of GP681 as single dose.
Conditions
- Healthy Volunteers
- Hepatic Impairment
Interventions
GP681Drug
GP681, tablet, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak plasma concentration (Cmax) of the analyte in plasma after oral administration of GP681Time frame: Day 1 to Day12
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration after oral administration of GP681Time frame: Day 1 to Day12
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after oral administration of GP681Time frame: Day 1 to Day12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing You'an Hospital, Beijing Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.